LIQOMICS | Hodgkin Lymphoma | circulating tumor DNA (ctDNA)

Mail Us

contact@liqomics.com

Call Us

(+49) 221 69 056 597

Publications

Here are some publications from our early development showing applications in Hodgkin Lymphoma and CNS Lymphoma.

Heger et al

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA. Blood (2024) 143 (6): 522–534.
(LINK: https://doi.org/10.1182/blood.2023022020 )

Sobesky et al

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection. Med (2021) 2 (10), 1171-1194.
(LINK: https://doi.org/10.1016/j.medj.2021.09.002 )

Heger et al

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. Journal of Clinical Oncology (2024)
(LINK: https://doi.org/10.1200/JCO.23.01867 )

Conference Talks

We presented validation data for LymphoVista and LymphoVista HL at the International Symposium on Hodgkin Lymphoma (ISHL) 2024 in Cologne, Germany and at the American Society of Hematology (ASH) meeting 2024 in San Diego, USA

Videos

Playlist

11 Videos

Challenges in understanding the genomic landscape of Hodgkin lymphoma

The importance of risk-adapted therapies in Hodgkin lymphoma

ICML 2023 The current state of MRD in Hodgkin lymphoma

ISHL12 2022 Current and future perspectives for prognostication and MRD in Hodgkin lymphoma

ISHL12 2022 Improving tools and techniques for MRD detection in Hodgkin lymphoma

ISHL HL Update 2021 Response biomarkers in HL

ctDNA and liquid biopsies in HL

Challenges and questions surrounding the use of liquid biopsy in lymphoma

ASH 2022 Using peripheral blood ctDNA-sequencing for PCNSL risk profiling

Using peripheral blood ctDNA-sequencing for PCNSL risk profiling

Can ctDNA be used to detect MRD in Hodgkin lymphoma?

Play Video

At LIQOMICS we strive to improve cancer treatment. Requiring only a blood sample, we use circulating tumor DNA to understand the genetics of an individual cancer and monitor treatment with razor-sharp sensitivity.

Other Pages

Contact Details

Follow us

Email us

contact[at]liqomics.com

Copyright © 2025 All rights reserved.